Committee for Orphan Medicinal Products (COMP) January 2012 highlights


London, England (January 16, 2012) – During its first meeting in 2012, the Committee for Orphan Medicinal Products (COMP) adopted a total of 16 recommendations for orphan designation, including for a number of substances intended for the treatment of diseases for which no orphan designation has ever been granted, and a substance intended for the treatment of a neglected tropical disease.


Orphan designation can be granted early in the development process to substances that are intended for diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than 5 in 10,000 people in the European Union (EU) or that would not be developed without incentives.


The COMP recommended the granting of an orphan designation for carbetocin for the treatment of Prader-Willi syndrome. This is the first orphan designation opinion for the treatment of this rare genetic condition. Prader-Willi syndrome causes a wide range of symptoms, such as a constant desire to eat food, which seems to be driven by permanent hunger and often leads to dangerous obesity, impaired function of the gonads, learning difficulties and behavioural problems. This is a seriously debilitating disease and patients often have a significantly reduced life span and require lifelong care.


At present there is no treatment approved for this rare condition, which is estimated to affect less than 2 in 10,000 people in the EU. Orphan designation gives the sponsor of carbetocin access to incentives that encourage and support the development of this medicine for the treatment of Prader-Willi syndrome.


The assessment of the designation application for carbetocin was supported by the expert advice from patient representatives from the European Organisation for Rare Diseases ( (Eurordis), who confirmed the high unmet medical need in the management of patients with Prader-Willi syndrome.


Another first-time orphan designation recommended by the COMP at its January 2012 meeting is for sialic acid in the treatment of hereditary inclusion body myopathy (HIBM). This is a very rare, debilitating neuromuscular disease with devastating consequences for patients, leading to many years of severe disability and near quadriplegia in muscle function. It is estimated that 4 in 10,000,000 people in Europe are affected by the condition.


The COMP adopted a recommendation for orphan designation for oleylphosphocholine for the treatment of leishmaniasis. The disease is caused by parasites that are transmitted through the bite of the sandfly.


The World Health Organization describes leishmaniasis as a poverty-related disease, which is endemic in many developing countries. The visceral form of leishmaniasis, the most serious form of the disease, is estimated to cause as many as 50,000 deaths per year. Nevertheless, in the EU the medicine is recommended for orphan designation because of the small number of patients affected in this region (less than 5 in 10,000). The framework for orphan medicines can also be used to support the fight against neglected diseases by providing incentives to encourage the development of medicines for these diseases that would not be developed under normal market conditions.


For the full list of opinions adopted by the COMP during its January 2012 meeting please see the COMP monthly report (



Next steps


The COMP recommendations for these substances are sent to the European Commission for the adoption of a decision. Once an orphan designation has been granted, sponsors have access to certain incentives ( during the development of the medicine.


For each medicine that has been granted an orphan designation, the Agency publishes a summary of the opinion on its website.



European Medicines Agency (EMA), 16.01.2012 (tB).a


Fitness watches generate useful information, but increase patient anxiety
A new device provides added protection against COVID-19 during endoscopic…
81 million Americans lacking space or bathrooms to follow COVID…
Front-line physicians stressed and anxious at work and home
EULAR: High-Dose Glucocorticoids and IL-6 Receptor inhibition can reduce COVID-19…


Morbus Fabry mittels Datenanalysen aus dem PraxisRegister Schmerz aufspüren
Neandertaler besaßen niedrigere Schmerzschwelle
Deutscher Schmerz- und Palliativtag 2020 – ONLINE
Deutsche Gesellschaft für Schmerzmedizin fordert Anerkennung von Nicht-Psychologen in der…
DBfK: Besondere Rolle für Pflegeexpert/innen Schmerz – nicht nur in…


“Körperstolz”: Michael Krauser managt seinen Diabetes digital
Der richtige Sensor – von Anfang an
Diabetes mellitus: Ein Risikofaktor für frühe Darmkrebserkrankungen
Fastenmonat Ramadan: Alte und neue Herausforderung für chronisch Erkrankte während…
Sanofi setzt sich für die Bedürfnisse von Menschen mit Diabetes…


Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren
Gesundheitliche Auswirkungen des Salzkonsums bleiben unklar: Weder der Nutzen noch…
Fast Food, Bio-Lebensmittel, Energydrinks: neue Daten zum Ernährungsverhalten in Deutschland
Neue Daten zur Ernährungssituation in deutschen Krankenhäusern und Pflegeheimen: Mangelernährung…
Baxter: Parenterale Ernährung von Patienten mit hohem Aminosäurenbedarf


Darolutamid bei Prostatakarzinom: Hinweis auf beträchtlichen Zusatznutzen
Multiples Myelom: Wissenschaftler überprüfen den Stellenwert der Blutstammzelltransplantation
Neues zur onkologischen Supportiv- und Misteltherapie und aktuelle Kongress-Highlights zum…
Finanzierung der ambulanten Krebsberatung weiterhin nicht gesichert
Lungenkrebsscreening mittels Low-Dose-CT


Geschützt: Multiple Sklerose: Novartis’ Siponimod verzögert Krankheitsprogression und Hirnatrophie bei…
Neurofilamente als Diagnose- und Prognosemarker für Multiple Sklerose
Bedeutung der Langzeittherapie bei Multipler Sklerose – mehr Sicherheit und…
Bristol Myers Squibb erhält Zulassung der Europäischen Kommission für Ozanimod…
Einige MS-Medikamente könnten vor SARS-CoV-2/COVID-19 schützen


Neue Studie zur tiefen Hirnstimulation bei Parkinson-Erkrankung als Meilenstein der…
Putzfimmel im Gehirn
Parkinson-Patienten in der Coronakrise: Versorgungssituation und ein neuer Ratgeber
Neuer Test: Frühzeitige Differenzialdiagose der Parkinson-Erkrankung
Gegen das Zittern: Parkinson- und essentiellen Tremor mit Ultraschall behandeln…